C
37.35
-0.87 (-2.28%)
| Penutupan Terdahulu | 38.22 |
| Buka | 38.19 |
| Jumlah Dagangan | 997,586 |
| Purata Dagangan (3B) | 1,211,857 |
| Modal Pasaran | 3,910,743,808 |
| Harga / Jualan (P/S) | 2.47 |
| Harga / Buku (P/B) | 3.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Operasi (TTM) | -30,860.11% |
| EPS Cair (TTM) | -3.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -43.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.05% |
| Nisbah Semasa (MRQ) | 22.53 |
| Aliran Tunai Operasi (OCF TTM) | -261.57 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -155.77 M |
| Pulangan Atas Aset (ROA TTM) | -20.13% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Crinetics Pharmaceuticals, Inc. | Menurun | Menaik |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.10 |
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.03% |
| % Dimiliki oleh Institusi | 112.39% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 96.00 (Citizens, 157.03%) | Beli |
| Median | 80.00 (114.19%) | |
| Rendah | 67.00 (Goldman Sachs, 79.38%) | Beli |
| Purata | 81.00 (116.87%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 47.33 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citizens | 02 Mar 2026 | 96.00 (157.03%) | Beli | 40.68 |
| 08 Jan 2026 | 105.00 (181.12%) | Beli | 53.24 | |
| Goldman Sachs | 12 Jan 2026 | 67.00 (79.38%) | Beli | 55.35 |
| Morgan Stanley | 06 Jan 2026 | 80.00 (114.19%) | Beli | 45.95 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| OKEY STEPHANIE | - | 40.12 | -3,000 | -120,360 |
| SCHILKE TOBIN | - | 40.12 | -6,713 | -269,326 |
| Jumlah Keseluruhan Kuantiti Bersih | -9,713 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -389,686 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 40.12 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SCHILKE TOBIN | Pegawai | 03 Mar 2026 | Jual automatik (-) | 6,713 | 40.12 | 269,326 |
| OKEY STEPHANIE | Pengarah | 03 Mar 2026 | Jual automatik (-) | 3,000 | 40.12 | 120,360 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |